222 related articles for article (PubMed ID: 36413432)
1. Biologics for eosinophilic granulomatosis with polyangiitis.
Caminati M; Maule M; Bello F; Emmi G
Curr Opin Allergy Clin Immunol; 2023 Feb; 23(1):36-43. PubMed ID: 36413432
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
3. New-onset of eosinophilic granulomatosis with polyangiitis without eosinophilia and eosinophilic infiltration under benralizumab treatment: A case report.
Yonezawa H; Ohmura SI; Ohkubo Y; Otsuki Y; Miyamoto T
Mod Rheumatol Case Rep; 2023 Dec; 8(1):145-149. PubMed ID: 37243733
[TBL] [Abstract][Full Text] [Related]
4. Torasemide-induced Vascular Purpura in the Course of Eosinophilic Granulomatosis with Polyangiitis.
Frątczak A; Polak K; Miziołek B; Bergler-Czop B
Acta Dermatovenerol Croat; 2022 Sep; 30(2):116-118. PubMed ID: 36254546
[TBL] [Abstract][Full Text] [Related]
5. A Review of Anti-IL-5 Therapies for Eosinophilic Granulomatosis with Polyangiitis.
Koike H; Nishi R; Yagi S; Furukawa S; Fukami Y; Iijima M; Katsuno M
Adv Ther; 2023 Jan; 40(1):25-40. PubMed ID: 36152266
[TBL] [Abstract][Full Text] [Related]
6. [Benralizumab in cases of eosinophilic granulomatosis with polyangiitis].
Carrette A; Mercier V; Lelubre C; Peché R
Rev Mal Respir; 2022 Sep; 39(7):621-625. PubMed ID: 35909008
[TBL] [Abstract][Full Text] [Related]
7. Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report.
Ide H; Shimizu T; Koike Y; Abe K; Shigematsu K; Nishihata S; Kojima K; Ichinose K; Kawakami A
Medicine (Baltimore); 2022 Nov; 101(44):e31401. PubMed ID: 36343053
[TBL] [Abstract][Full Text] [Related]
8. Combination of monoclonal antibodies targeting type 2 inflammation for severe asthma and eosinophilic granulomatosis with polyangiitis.
Davanzo F; Marchi MR; Iorio L; Bortoli M; Doria A; Padoan R
Autoimmun Rev; 2024 Mar; 23(3):103503. PubMed ID: 38101691
[TBL] [Abstract][Full Text] [Related]
9. Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation: Report from the European EGPA study group.
Caminati M; Fassio A; Alberici F; Baldini C; Bello F; Cameli P; Conticini E; Cottin V; Crimi C; Dagna L; Delvino P; Deroux A; Duran E; Espigol-Frigole G; Karadag O; Maule M; Moiseev S; Monti S; Moroni L; Padoan R; Pugnet G; Taille C; Toniati P; Vaglio A; Emmi G
Allergy; 2024 Feb; 79(2):516-519. PubMed ID: 37904674
[No Abstract] [Full Text] [Related]
10. Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis.
Nanzer AM; Maynard-Paquette AC; Alam V; Green L; Thomson L; Lam J; Fernandes M; Roxas C; d'Ancona G; Hearn A; Gates J; Agarwal S; Kent BD; Fernando M; D'Cruz DP; Hopkins C; Ismail TF; Dhariwal J; Jackson DJ
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):724-732. PubMed ID: 38211889
[TBL] [Abstract][Full Text] [Related]
11. Successful benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis.
Belfeki N; Abroug S; Ghriss N; Chouchane I; Hamrouni S; Strazzulla A; Zayet S
Clin Exp Rheumatol; 2021 Oct; 40(4):834-837. PubMed ID: 35522541
[TBL] [Abstract][Full Text] [Related]
12. The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review.
Kouverianos I; Angelopoulos A; Daoussis D
Rheumatol Int; 2023 Jul; 43(7):1245-1252. PubMed ID: 37085573
[TBL] [Abstract][Full Text] [Related]
13. A rare case report of polyangiitis overlap syndrome: granulomatosis with polyangiitis and eosinophilic granulomatosis with polyangiitis.
Quan MV; Frankel SK; Maleki-Fischbach M; Tan LD
BMC Pulm Med; 2018 Nov; 18(1):181. PubMed ID: 30497438
[TBL] [Abstract][Full Text] [Related]
14. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
[TBL] [Abstract][Full Text] [Related]
15. Eosinophilic granulomatosis with polyangitis: A new target for biologicals.
Bayrak Durmaz MS; Çelebi Sözener Z; Bavbek S
Tuberk Toraks; 2022 Mar; 70(1):93-101. PubMed ID: 35362309
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
McBrien CN; Menzies-Gow A
Drugs Today (Barc); 2018 Feb; 54(2):93-101. PubMed ID: 29637936
[TBL] [Abstract][Full Text] [Related]
17. Churg-Strauss syndrome.
Greco A; Rizzo MI; De Virgilio A; Gallo A; Fusconi M; Ruoppolo G; Altissimi G; De Vincentiis M
Autoimmun Rev; 2015 Apr; 14(4):341-8. PubMed ID: 25500434
[TBL] [Abstract][Full Text] [Related]
18. Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy.
Koga Y; Yoshimi S; Harada T; Suzuki S; Ohtsuka T; Dobashi K; Hisada T
Intern Med; 2023 May; 62(10):1553-1556. PubMed ID: 36171130
[TBL] [Abstract][Full Text] [Related]
19. ANCA-negative EGPA: only eosinophils without vasculitis? Insights from anti-T2 biologics.
Piga MA; Fraticelli P; Antonicelli L; Garritani MS; Ghirelli G; Martini M; Di Vincenzo A; Danieli MG; Moroncini G; Bilò MB
Front Immunol; 2023; 14():1325299. PubMed ID: 38090592
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic advances in eosinophilic granulomatosis with polyangiitis.
Ford JA; Aleatany Y; Gewurz-Singer O
Curr Opin Rheumatol; 2022 May; 34(3):158-164. PubMed ID: 35440531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
